We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

40 hedge funds and large institutions have $39.9M invested in Milestone Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $44K | Put options by funds: $27K

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

2.33% less ownership

Funds ownership: 58.99% → 56.66% (-2.3%)

9% less funds holding

Funds holding: 44 → 40 (-4)

29% less capital invested

Capital invested by funds: $56.4M → $39.9M (-$16.5M)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
40
Holders Change
-4
Holders Change %
-9.09%
% of All Funds
0.58%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
3
Increased
9
Reduced
6
Closed
6
Calls
$44K
Puts
$27K
Net Calls
+$17K
Net Calls Change
+$53K

Top Buyers

1
BCM
BML Capital Management
Indiana
+$798K
2
AFA
Alta Fundamental Advisers
New York
+$462K
3
Squarepoint
Squarepoint
New York
+$87.9K
4
LPC
Lion Point Capital
New York
+$64.3K
5
AI
Atria Investments
North Carolina
+$45K

Top Sellers

1
VCIM
Velan Capital Investment Management
Georgia
-$1.16M
2
MIM
Monashee Investment Management
Massachusetts
-$895K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$787K
4
SCM
Stonepine Capital Management
Oregon
-$359K
5
ACM
Altium Capital Management
New York
-$322K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$6.56M – – –
RI
2
RTW Investments
New York
$4.3M – – –
Millennium Management
3
Millennium Management
New York
$3.66M -$170K -105,682 -4%
AFA
4
Alta Fundamental Advisers
New York
$3.51M +$462K +287,300 +12%
LPC
5
Lion Point Capital
New York
$3.09M +$64.3K +40,000 +2%
Citadel Advisors
6
Citadel Advisors
Florida
$2.86M -$201K -125,060 -6%
O
7
OrbiMed
New York
$2.64M – – –
NCM
8
Nantahala Capital Management
Connecticut
$2.31M – – –
Goldman Sachs
9
Goldman Sachs
New York
$1.79M – – –
BL
10
Bleichroeder LP
New York
$1.75M – – –
SCM
11
Stonepine Capital Management
Oregon
$1.64M -$359K -223,097 -15%
BCM
12
BML Capital Management
Indiana
$1.46M +$798K +496,750 +82%
ACM
13
Altium Capital Management
New York
$1.34M -$322K -200,514 -17%
Morgan Stanley
14
Morgan Stanley
New York
$1.09M +$14.2K +8,826 +1%
IC
15
Ikarian Capital
Texas
$620K – – –
BC
16
Boxer Capital
California
$408K – – –
ACM
17
ADAR1 Capital Management
Texas
$267K – – –
AA
18
Ancora Advisors
Ohio
$79.2K – – –
Envestnet Asset Management
19
Envestnet Asset Management
Illinois
$78.6K +$12.4K +7,690 +15%
Squarepoint
20
Squarepoint
New York
$72.7K +$87.9K +54,684 New
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
$52.4K – – –
BFM
22
Boothbay Fund Management
New York
$40.6K – – –
AI
23
Atria Investments
North Carolina
$36.9K +$45K +27,991 New
Northern Trust
24
Northern Trust
Illinois
$36.7K -$855 -532 -2%
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$32.7K +$12.4K +7,700 +46%
1
2

MIST Hedge Fund Activity: Q2 2024 in Review

40 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2024, worth a combined $39.9M — down 29% from $56.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of MIST and 3 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 9 added.

The largest buyer was BML Capital Management, adding an estimated $798K. The largest seller was Velan Capital Investment Management, exiting entirely with an estimated $1.16M sold.

  • 40 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2024, down from 44 in Q1 2024.
  • Funds reported $39.9M of Milestone Pharmaceuticals stock for Q2 2024, down 29% quarter-over-quarter.
  • 3 funds opened new Milestone Pharmaceuticals positions in Q2 2024 and 6 closed out, a net change of -3 holders.
  • The largest Milestone Pharmaceuticals buyer in Q2 2024 was BML Capital Management, an estimated $798K added.
  • The largest Milestone Pharmaceuticals seller in Q2 2024 was Velan Capital Investment Management, an estimated $1.16M sold.

Based on aggregated 13F filings for Q2 2024.